Answers are grounded in this paper and cite their sources.
NCX 4016 and NCX 4215 demonstrate dual antiplatelet action in vitro via cyclo-oxygenase inhibition and nitric oxide release, with NCX 4016 being the more potent agent.
The antiplatelet activity of two new nitrocompounds, chemically related to acetylsalicylic acid (NCX 4215 and NCX 4016), was studied in vitro to verify the hypothetical dual action of these drugs. Both drugs, in a dose-dependent way, inhibited arachidonic acid-induced platelet aggregation and thromboxane A2 production, measured as thromboxane B2 concentration in whole blood. These effects are likely to be related to cyclo-oxygenase inhibition. NCX 4215 and NCX 4016 in a dose-dependent way inhibited also thrombin-induced aggregation of platelets pretreated with acetylsalicylic acid. These inhibitory effects are related to nitric oxide release and cGMP increase and significantly reversed by oxyhaemoglobin and methylene blue. Either as a cyclo-oxygenase inhibitor or as a nitric oxide donor, NCX 4016 proved to be significantly more potent than NCX 4215.
No takes yet. Share an insight, caveat, or question.
Lechi et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: